Detalle Publicación

ARTÍCULO
Baseline Interleukin-6 and-8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
Autores: Oecal, O.; Schuette, K.; Kupcinskas, J.; Morkunas, E.; Jurkeviciute, G.; de Toni, E. N.; Ben Khaled, N.; Berg, T.; Malfertheiner, P.; Klumpen, H. J. ; Sengel, C.; Basu, B.; Valle, J. W.; Benckert, J.; Gasbarrini, A.; Palmer, D.; Seidensticker, R.; Wildgruber, M.; Sangro Gómez-Acebo, Bruno Carlos; Pech, M.; Ricke, J.; Seidensticker, M.
Título de la revista: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
ISSN: 0171-5216
Volumen: 148
Número: 2
Páginas: 475 - 485
Fecha de publicación: 2022
Lugar: WOS
Resumen:
Purpose To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib. Methods A subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response. Results Forty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and 57.9 pg/mL most effectively predicted overall survival for IL-6 and IL-8, respectively. Patients with high IL-6 (HR, 4.1 [1.9-8.9], p < 0.001) and IL-8 (HR, 2.4 [1.2-4.7], p = 0.009) had significantly shorter overall survival than patients with low IL values. Multivariate analysis confirmed IL-6 (HR, 2.99 [1.22-7.3], p = 0.017) and IL-8 (HR, 2.19 [1.02-4.7], p = 0.044) as independent predictors of OS. Baseline IL-6 and IL-8 with respective cut-off values predicted objective response rates according to mRECIST in a subset of 42 patients with follow-up imaging available (IL-6, 46.6% vs. 19.2%, p = 0.007; IL-8, 50.0% vs. 17.4%, p = 0.011). Conclusion IL-6 and IL-8 baseline values predicted outcomes of sorafenib-treated patients in this well-characterized prospective cohort of the SORAMIC trial. We suggest that the respective cut-off values might serve for validation in larger cohorts, potentially offering guidance for improved patient selection.